title: [Intra-femoral artery injections in a hospital angiology clinic].
abstract: Intra-arterial injections of vasodilators are due to Henri Reboul. After a recent disfavor, the modern equipment together with a simple and detailed technique make it possible to easily do repeated injections. The only accidents are hematomas due to insufficient compression. Use of anticoagulants is the main counter-indication. Lidocain hydrochloride or pure scylocain 1% are the safest drugs. The antispasmodic papaverine, various vasodilators, antibiotics and heparin can be added. In out patient clinics, the rate of injections is one to three per week for a series of 10 injections at the most. Stage II arteritis is the ideal situation and successes are also found in stages III and IV. During the first visit for a acute phlebitis intra-arterial injection of scylocain with 100 mg. heparin makes it possible to start the necessary therapy with anticoagulants. The simple post-phlebitis venous edema seems a case in which the technique should be used.
mesh_terms: D000553:Ambulatory Care; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001167:Arteritis / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005263:Femoral Artery; D005500:Follow-Up Studies; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007269:Injections, Intra-Arterial / Q000009:adverse effects; D008012:Lidocaine / Q000008:administration & dosage* / Q000627:therapeutic use; D010208:Papaverine / Q000008:administration & dosage* / Q000627:therapeutic use; D010689:Phlebitis / Q000188:drug therapy; D013997:Time Factors; D014652:Vascular Diseases / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D014665:Vasodilator Agents; D006493:Heparin; D008012:Lidocaine; D010208:Papaverine
vernacular_title: Les injections intra-artérielles fémorales en consultation hospitaliére d'angéiologie.